title: Comparison of surveillance and retroperitoneal lymph node dissection in Stage I nonseminomatous germ cell tumors.
abstract: OBJECTIVE
  To compare retrospectively the treatment results of surveillance and primary retroperitoneal lymph node dissection (RPLND) of patients with clinical Stage I nonseminomatous germ cell tumors of the testis (NSGCT) in two institutions in The Netherlands.
  
  
  METHODS
  From 1982 to 1994, 90 consecutive patients with clinical Stage I NSGCT were prospectively entered in a surveillance protocol in Amsterdam (group 1). In the same period, 101 patients with clinical Stage I NSGCT underwent primary RPLND in Nijmegen (group 2). Both patient populations were comparable for patient age, presence of vascular invasion, and embryonal cell components in the primary tumor. All patients in group 1 with relapse, except for 2, were treated with cisplatin-based chemotherapy. All patients in group 2 with vital tumor in the RPLND specimen were treated with two adjuvant courses of combined chemotherapy (cisplatin, etoposide, and bleomycin).
  
  
  RESULTS
  In group 1, at a median follow-up of 7.7 years, 23 patients (26%) had relapse. The median time to relapse was 12 months. Relapses were located retroperitoneally (n = 18, 78%), in the lung (n = 3, 13%), scrotally (n = 1, 4%), and combined in the liver, lung, and pleura (n = 1, 4%). After treatment of relapses (chemotherapy in 21 and/or surgery in 11), only 1 patient died of disseminated disease. A disease-free survival rate of 98.5% was achieved at the median follow-up. The main toxicities consisted of short-lasting leukopenia, accompanied by infection (13%). Four patients reported cardiovascular and four neuropathy complaints. In group 2, the median follow-up was 6.9 years. In 31 patients (30.7%), vital tumor was found retroperitoneally; after two courses of combined chemotherapy, none of them had a relapse. Seven patients with pathologic Stage I disease (6.4%) had a pulmonary relapse within 1 year after surgery. No retroperitoneal relapses were found. After chemotherapy, 6 patients with relapse were salvaged, and 1 died of disseminated disease. The disease-specific survival rate in group 2 was 98% at the median follow-up. The most frequent surgical complications were lymphocele (n = 3), small bowel obstruction (n = 3), and abdominal pain (n = 3). The antegrade ejaculation rate was 94%.
  
  
  CONCLUSIONS
  Excellent treatment results in terms of disease-free survival can be achieved in Stage I NSGCT with both surveillance and primary RPLND. Patients with pathologic Stage II disease adjuvantly treated with chemotherapy did not have any relapse and consequently all survived. Most complications after both treatment strategies are reversible. The choice of treatment should be based on balanced information and not on dogmatic principles.
authors.affiliation: Department of Urology, University Medical Center Nijmegen, Nijmegen, The Netherlands.
authors.forename: J R
authors.initials: JR
authors.lastname: Spermon
authors.forename: T A
authors.initials: TA
authors.lastname: Roeleveld
authors.forename: H G
authors.initials: HG
authors.lastname: van der Poel
authors.forename: C A
authors.initials: CA
authors.lastname: Hulsbergen-van de Kaa
authors.forename: W W
authors.initials: WW
authors.lastname: Ten Bokkel Huinink
authors.forename: M
authors.initials: M
authors.lastname: van de Vijver
authors.forename: J A
authors.initials: JA
authors.lastname: Witjes
authors.forename: S
authors.initials: S
authors.lastname: Horenblas
mesh_terms: D000293:Adolescent; D000328:Adult; D004542:Ejaculation; D018237:Germinoma / Q000556:secondary* / Q000601:surgery*; D006801:Humans; D008197:Lymph Node Excision; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D012187:Retroperitoneal Space; D012189:Retrospective Studies; D018571:Sentinel Surveillance; D013736:Testicular Neoplasms / Q000473:pathology / Q000601:surgery*